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Abstract
Background: Men with type 2 diabetes mellitus (T2D) often have lowered testosterone levels and an increased risk of 
cardiovascular disease (CVD). Ectopic fat increases the risk of CVD, whereas subcutaneous gluteofemoral fat protects 
against CVD and has a beneficial adipokine-secreting profile.
Hypothesis: Testosterone replacement therapy (TRT) may reduce the content of ectopic fat and improve the adipokine 
profile in men with T2D.
Design and methods: A randomized, double-blinded, placebo-controlled study in 39 men aged 50–70 years with T2D 
and bioavailable testosterone levels <7.3 nmol/L. Patients were randomized to TRT (n = 20) or placebo gel (n = 19) for 
24 weeks. Thigh subcutaneous fat area (TFA, %fat of total thigh volume), subcutaneous abdominal adipose tissue 
(SAT, % fat of total abdominal volume) and visceral adipose tissue (VAT, % fat of total abdominal volume) were 
measured by magnetic resonance (MR) imaging. Hepatic fat content was estimated by single-voxel MR spectroscopy. 
Adiponectin and leptin levels were measured by in-house immunofluorometric assay. Coefficients (b) represent the 
placebo-controlled mean effect of intervention.
Results: TFA (b = −3.3 percentage points (pp), P = 0.009), SAT (b = −3.0 pp, P = 0.006), levels of adiponectin (b = −0.4 mg/L, 
P = 0.045), leptin (b = −4.3 µg/mL, P < 0.001), leptin:adiponectin ratio (b = −0.53, P = 0.001) and HDL cholesterol 
(b = −0.11 mmol/L, P = 0.009) decreased during TRT compared with placebo. Hepatic fat content and VAT were 
unchanged.
Conclusions: The effects of TRT on cardiovascular risk markers were ambiguous. We observed potentially harmful 
changes in cardiovascular risk parameters, markedly reduced subcutaneous fat and unchanged ectopic fat during 
TRT and a reduction in adiponectin levels. On the other hand, the decrease in leptin and leptin:adiponectin ratio 
assessments could reflect an amelioration of the cardiovascular risk profile linked to hyperleptinaemia in ageing men 
with T2D.
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Introduction
The safety of long-term testosterone replacement 
therapy (TRT) has not been clarified regarding the risk 
of cardiovascular disease (CVD) (1, 2, 3). Nonetheless, 
the usage of TRT has escalated in the Western countries 
during the past decades especially in ageing men without 
clear organic indication for TRT (4). Ageing men with 
type 2 diabetes mellitus (T2D) often have lowered 
testosterone levels (5), ectopic fat depots (6), a deranged 
adipokine profile with e.g. low adiponectin levels (7), 
hyperleptinaemia (8) and an increased risk of CVD (5, 9). 
However, the causal relations are unclear, and lowered 
testosterone levels could simply be a marker of illness, i.e. 
T2D and obesity (9). Non-obese, hypogonadal men may 
have more subcutaneous fat compared with eugonadal 
men, whereas no difference is found regarding visceral 
adipose tissue (VAT) (10). Regional fat distribution affects 
the CVD risk of which lower body subcutaneous fat 
storage protects against CVD (11) and represents a normal 
physiological expansion of nonpathogenic adipocytes 
(12). On the other hand, ectopic fat such as VAT (11) and 
non-alcoholic fatty liver disease (NAFLD) (13, 14) are 
associated with increased CVD risk (11, 13) and might 
contribute to the pathogenesis of insulin resistance (13, 
15, 16). Irrespective of testosterone levels, ectopic fat 
storage occurs when continuous nutritional overload 
leads to adipocyte expansion failure in the subcutaneous 
fat compartments, resulting in the redistribution of 
fat to the liver, muscle and VAT (17). This fat storage 
at ectopic sites is further promoted by aging in itself 
(18). Theoretically, TFA is more protective against CVD 
risk compared to SAT (19, 20) possibly due to a long-
term entrapment of excess free fatty acids (FFA) (11, 
21) and a more favourable adipokine-secreting profile. 
There is evidence of a primary secretion of leptin from 
the subcutaneous compartments (20, 22) though leptin 
levels might be associated with VAT in obese men (20). 
A deranged adipokine secretion contributes to CVD (23) 
as elevated adiponectin levels may inhibit inflammation 
(24) and atherosclerosis (25), whereas the role of leptin 
is a double-edged sword. Healthy lean individuals are 
in a low leptin state where leptin regulates food intake 
and has insulin-sensitizing effects (23, 26), whereas 
hyperleptinaemia in obesity and/or T2D is associated with 
an increased risk of CVD (27). Hyperleptinaemia without 
a concomitant increase in leptin activity is a state called 
leptin resistance (18). The index of leptin levels corrected 
by adiponectin concentrations (leptin:adiponectin ratio) 
could be a better cardio-metabolic marker than levels of 
adiponectin and leptin alone (28, 29).
There is evidence that TRT may reduce ectopic fat 
deposition and improve the adipokine profile in ageing 
men with and without T2D (30, 31, 32, 33, 34, 35, 36) 
possibly through the inhibition of the adipogenic lineage 
(37, 38). A beneficial effect on ectopic fat deposition is 
consistent with reports showing that TRT increases lipid 
oxidation in hypopituitary men (39, 40) and in ageing 
men without T2D (41), but could also simply reflect an 
overall effect of TRT on total fat mass (35, 41, 42). In 
ageing men with T2D, regional abdominal adipose tissue 
during TRT has only been assessed in one former study 
by a validated tool i.e. magnetic resonance imaging (MRI) 
reporting unchanged VAT and decreased SAT, whereas 
TFA was not reported (31). One previous study has 
evaluated the efficacy of TRT on the content of hepatic fat 
in ageing men with T2D (30) and the sparse reports on the 
content of hepatic fat in men without T2D during TRT are 
conflicting probably due to different assessment methods, 
inhomogeneous groups of included patients e.g. large age 
spans and varying biochemical cutoffs for hypogonadism 
(32, 33, 34, 36). In theory, a reduction of SAT may result 
in a beneficial change in the adipokine profile with an 
increase in adiponectin levels and a decrease in leptin 
concentrations (43, 44). Previous papers evaluating 
levels of adiponectin and leptin during TRT are however 
inconsistent in aging men with T2D (30, 31, 45, 46).
In the present study, we hypothesized that TRT reduces 
the content of ectopic fat and improves the adipokine 
profile in men with T2D during TRT in ageing men with 
T2D and lowered bioavailable testosterone (BioT) levels.
Subjects and methods
This 24-week, randomized, double-blinded, placebo-
controlled trial was conducted at Odense University 
Hospital (Denmark) from April 2012 to November 2013. 
The study was approved by the Local Ethics Committee 
and the Danish Health and Medicines Authority. The 
trial was declared in ClinicalTrials.gov (identifier: 
NCT01560546), and all patients gave written informed 
consent at the screening visit. To find eligible patients, 
we used advertisement at general practitioners, in 
magazines, newspapers, and through written invitations 
to patients with newly diagnosed T2D, who were referred 
to the Department of Endocrinology at Odense University 
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Hospital. The inclusion criteria included men, aged 
50–70  years, T2D diagnosed within the last 10  years, 
metformin treated for at least 3 months and a bioavailable 
testosterone level <7.3 nmol/L. The main exclusion 
criteria were BMI ≥40 kg/m2, haematocrit >50%, known 
malignant disease, PSA >3 μg/L, nycturia >3 times, 
clinically significant disease of the heart, lung or kidneys, 
abnormal routine blood samples, severe untreatable 
hypertension, former or present abuse of alcohol or 
medicine/drugs within a year, primary or secondary 
hypogonadism, ongoing severe mental illness, wish of 
fatherhood and treatment with morphine, 5α reductase 
inhibitors, oral glucocorticoid steroids or antidiabetic 
medications apart from metformin. In all, 59 patients 
attended a screening visit, 43 patients were eligible and 
included and 39 patients completed the study.
Patients were randomly assigned to 5 g gel daily 
containing placebo (n = 21) or 50 mg testosterone, Testim 
(n = 22). In total, 19 patients in the placebo group and 20 
patients in the TRT group completed the study. Due to 
obesity, claustrophobia and failure in the acquisition of 
the MRI/MRS scans, nine patients in the placebo group 
and 10 patients in the TRT group failed MRI/MRS scans. 
Patients were informed not to change their diet, and they 
were allowed to continue habitual activities throughout 
the study. Two non-testosterone-related serious adverse 
events occurred in the study as reported previously (35). 
The study design, population, assays along with data and 
methods of evaluation on testosterone levels, lean body 
mass, total fat mass, lipids and insulin sensitivity are 
reported in further detail elsewhere (35).
All patients were on a stable antidiabetic treatment 
regimen throughout the entire study and only 
metformin was allowed. Concomitant medication, 
i.e. antihypertensive, cholesterol lowering and anti-
thrombotic drugs, was equally distributed between the 
placebo and testosterone groups, which was also the case 
regarding the subgroups undergoing MRI and/or MRS. We 
examined the patients on two consecutive days before and 
after 24 weeks of TRT. Dose titration was performed after 
three weeks treatment with an increase to 10 g gel daily if 
BioT levels <7.3 nmol/L. Safety monitoring was externally 
handled to ensure continued blinding and included 
evaluation of PSA, haematocrit and haemoglobin after 3, 
12 and 24 weeks of treatment.
Magnetic resonance imaging (MRI)
MRI was performed with a 3.0-T high-field MR Unit 
(Phillips Achieva, Phillips Healthcare). Three  abdominal 
slices (10 mm thick, 20 mm apart, lower slice at 
the dorsal, intervertebral space of L4/L5) and one 
femoral slice (15 cm from the major trochanter and 
perpendicular to subcutaneous fat) were recorded using 
an axial, T1-weighted gradient-echo sequence. In-house 
developed software using MATLAB (MathWorks, Natick, 
Massachusetts, United States) was applied for automatic 
segmentation of the images, yielding SAT (% fat of total 
abdominal volume), VAT (% fat of total abdominal volume) 
and TFA (% fat of total thigh volume). First, the images 
were bias-corrected (47). The different compartments were 
then automatically delineated by unrolling the images 
and using the graph-cut method (48). The threshold for 
fat was determined as the 4th cluster using a k-means 
clustering with 5 groups.
Magnetic resonance spectroscopy (MRS)
Single-voxel liver 1H MRS was performed to measure the 
hepatic fat content. MRS measurements were performed 
using a Philips Achieva 3.0-T MR scanner (Philips 
Healthcare). Liver MR images in all three planes were 
used to localize voxels for MRS. The MR spectroscopic 
data were acquired using a SENSE XL torso coil with 16 
channels, following shimming, with volumes of interest 
(30 × 30 × 30 mm3) manually placed within the right 
lobe of the liver (segment six or seven), avoiding major 
blood vessels, intrahepatic bile ducts and the lateral 
margins of the liver in all dimensions. The point-resolved 
spectroscopy (PRESS) technique was performed without 
water suppression (repetition time ms/echo time ms, 
2000/35). We collected spectra during a single breath-
hold (17.5 s). The water peak and the major fat peak of 
methylene, located at 4.7 and 1.3 ppm respectively, were 
automatically fitted by using a spectroscopic analysis 
package included in the Philips workstation. Area ratios 
(hepatic fat/water ratio) were calculated for each patient 
(Supplementary Fig. 1, see section on supplementary data 
given at the end of this article). Automated spectral results 
were reviewed by an experienced MR spectroscopist who 
was blinded to the treatment allocation.
Euglycemic–hyperinsulinemic clamp
After an overnight fast, a 2-h basal tracer equilibration 
period was followed by a 4-h period with insulin infusion 
at a rate of 40 U/m2/min. A [3-3H]-glucose infusion was 
used throughout the 6-h study, and [3-3H]-glucose was 
added to the glucose infusates to maintain plasma-specific 
activity constant at baseline levels during the 4-h clamp 
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period. By varying the infusion of 20% glucose based on 
bedside plasma glucose measurements every 10–20 min, 
plasma glucose was kept constant at approximately 
5.5 mmol/L. Steele’s non-steady-state formulas were used 
to calculate the rates of total glucose appearance (Ra) and 
glucose disposal (Rd). Insulin-stimulated Rd was taken as 
an estimate of whole-body insulin sensitivity.
Biochemical assays
Adiponectin (mg/L) was determined by a validated 
in-house time-resolved immunofluorometric assay based 
on two monoclonal antibodies and recombinant human 
adiponectin (obtained from R&D Systems) (49). The 
intra-assay coefficient of variation averaged <10%. Leptin 
(µg/L) was determined by a validated in-house time-
resolved immunofluorometric assay based on commercial 
reagents (from R&D Systems: two monoclonal antibodies 
(cat. no. MAb 398 for coating and BAM 398 for detection) 
and recombinant human leptin as standard (cat. no. 398-
LP)) and carried out essentially as the adiponectin time-
resolved immunofluorometric assay (49). The recovery of 
exogenous leptin added to serum averaged 96.8 ± 0.2% 
(the intra-assay CV averaged 50 assay setups).
Analysis of ALAT and GGT were performed 
in a Modular System (Roche Diagnostics) with 
dedicated reagents.
Statistical methods
The sample size of the study was determined by the 
anticipated effect of TRT on lean body mass (42) with an 
assumption of type 1 error (α) = 0.05, type 2 error (β) = 0.1, 
s.d. = 1.3 kg, along with a 25% drop-out rate, resulting in 20 
patients in each group. In the present study, the primary 
outcome measures included changes in SAT, TFA, VAT, 
hepatic fat content and levels of adiponectin and leptin. 
The changes in SAT, TFA and VAT are given as percentage 
points (pp). Per-protocol analyses were performed. 
Differences in baseline values were analysed using unpaired 
t-test on normally distributed data. Wilcoxon rank-sum 
tests were conducted at baseline and on delta values if data 
could not be transformed to normally distributed data 
using natural logarithm. Outcome measurements were 
assessed by multiple linear regression analyses controlled 
for baseline values on normally distributed data for the 
placebo-controlled mean effect of intervention between 
groups (b). The models were checked with residual 
plots and Box–Cox analysis. Absolute changes during 
24 weeks from baseline are given as delta values. We used 
non-parametric Spearman’s rank correlation to analyse 
the correlations between delta values. All tests were 
done two-sided and results of P < 0.05 were considered 
statistically significant. Results are expressed as arithmetic 
mean ± s.d., geometric mean (95% CI) or median 
(interquartile range) as appropriate. Statistical analyses 
were performed with STATA, version 13.
Results
The testosterone and placebo groups were comparable 
regarding all baseline measurements (Tables 1 and 2).
Total fat mass (TFM), SAT, TFA, VAT, hepatic fat 
content and body composition
As reported, TFM (b = −1.3 kg, P = 0.009) was reduced during 
TRT compared with placebo (n = 39) (35) and TFM was also 
reduced (b = −1.1 kg, P = 0.045) during TRT compared with 
placebo in the subgroups undergoing MRI and/or MRS 
(n = 27) (Table  2). This was accompanied by reductions 
in SAT (b = −3.0 pp) and TFA (b = −3.3 pp) during TRT 
compared with placebo. There was no change in hepatic 
fat content or VAT during TRT compared with placebo 
(Fig. 1 and Table 1). Total lean body mass was increased, 
while body weight, BMI and waist circumference (WC) 
were unaltered (35).
Adipokines, lipids, liver enzymes and 
insulin sensitivity
Adiponectin (b = −0.4 mg/L), leptin (b = −4.3 µg/L), 
leptin:adiponectin ratio (b = −0.53) and GGT (b = −7.8 U/L) 
levels decreased, while ALAT was unchanged during TRT 
compared with placebo (Fig. 2 and Table 1). As reported, 
HDL cholesterol (b = −0.11 mmol/L) was decreased 
while total cholesterol, LDL cholesterol, TG, HOMA-IR 
and insulin-stimulated glucose disposal rate (Rd) were 
unchanged (35).
Correlations
At baseline in all patients
We examined the correlations between leptin, adiponectin 
and CVD risk modifiers.
Adiponectin was positively associated with age and 
HDL cholesterol, while adiponectin was negatively 
associated with TG and HOMA-IR (Table 3).
Leptin was positively associated with BMI, WC, TFM, 
VAT, hepatic fat content and HOMA-IR, whereas leptin 
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was negatively associated with testosterone levels (TT, BT, 
FT and DHT), SHBG and insulin-stimulated Rd (Table 3).
Leptin:adiponectin ratio was positively correlated 
to BMI, WC, TFM, VAT, hepatic fat content, TG and 
HOMA-IR, whereas leptin:adiponectin ratio was negatively 
correlated to HDL, TT, DHT, SHBG and insulin-stimulated 
Rd (Table 3).
Hepatic fat content was positively associated with 
BMI, WC, TFM, ALAT and HOMA-IR, whereas hepatic fat 
content was negatively associated with insulin-stimulated 
Rd (Table 4).
Δ24 weeks-baseline in the testosterone group
We performed correlations between the changes of 
possible CVD risk modifiers and changes in levels of 
adiponectin and leptin after TRT. Δ-Adiponectin levels 
were positively associated with Δ-HDL cholesterol 
Table 1 Clinical and para clinical characteristics. Data are presented as arithmetic mean ± s.d. Bold type indicates statistically 
significant differences.
 Testosterone Placebo
 
P value  n Values n Values
TFA/TTA (%)# 12  13   
 Baseline  30.7 (26.1–36.1)  27.9 (24.0–32.3)  
 24 weeks  27.3 (22.8–32.7)  28.0 (24.2–32.4)  
 ∆ 24-week baseline†  −3.7 (−4.9; −2.4)  −0.8 (−1.7; 1.2) 0.009
TMA/TTA (%)# 12  13   
 Baseline  8.4 (7.5–9.4)  8.6 (7.4–9.9)  
 24 weeks  8.0 (7.1–9.0)  8.3 (6.8–10.1)  
 ∆ 24-week baseline†  −0.4 (−1.2; 0.1)  −0.0 (−0.8; 0.2) 0.79
VAT/TAT (%)# 12  13   
 Baseline  22.0 (18.4–26.3)  23.2 (20.8–25.8)  
 24 weeks  21.4 (17.1–26.6)  22.6 (20.3–25.1)  
 ∆ 24-week-baseline†  −0.1 (−2.3; 1.5)  −0.4 (−1.4; 0.2) 0.91
SAT/TAT (%)# 12  13   
 Baseline  32.1 (28.0–36.7)  31.4 (28.7–34.5)  
 24 weeks  28.7 (24.7–33.5)  31.2 (28.7–33.8)  
 ∆ 24-week baseline†  −2.6 (−4.9; −1.2)  −0.8 (−1.9; 1.0) 0.006
Hepatic fat/water ratio† 11  11   
 Baseline  0.39 (0.10; 0.59)  0.40 (0.16; 0.73)  
 24 weeks  0.25 (0.05; 0.66)  0.24 (0.15; 0.53)  
 ∆ 24-week-baseline  0.00 (−0.05; 0.04)  −0.10 (−0.31; 0.01) 0.12
ALAT (U/L)# 20  19   
 Baseline  31.8 (25.2–40.2)  33.9 (27.3–42.0)  
 24 weeks  29.5 (22.5–38.5)  34.8 (27.1–44.5)  
 ∆ 24-week baseline†  −1.5 (−7.0; 4.5)  −1.0 (−2.0; 8.0) 0.27
GGT (U/L)# 20  19   
 Baseline  33.5 (25.4–44.3)  39.7 (32.7–48.2)  
 24 weeks  29.3 (22.1–38.7)  42.4 (34.4–52.2)  
 ∆ 24-week baseline†  −2.0 (−10.0; 0.5)  0.0 (−6.0; 8.0) 0.019
Adiponectin (mg/L)# 20  19   
 Baseline  7.5 (6.1–9.3)  6.2 (5.1–7.6)  
 24 weeks  6.8 (5.5–8.4)  6.1 (5.2–7.2)  
 ∆ 24-week baseline†  −0.7 (−1.2; −0.2)  −0.2 (−0.8; 0.4) 0.045
Leptin (µg/L)# 20  19   
 Baseline  13.2 (10.0–17.5)  11.6 (9.0–14.9)  
 24 weeks  9.5 (6.8–13.2)  12.4 (9.6–16.0)  
 ∆ 24-week-baseline†  −3.7 (−5.4; −1.3)  0.4 (−1.8; 3.6) <0.001
LAR# 20  19   
 Baseline  1.8 (1.2–2.6)  1.9 (1.4–2.5)  
 24 weeks  1.4 (0.9–2.2)  2.0 (1.5–2.7)  
 ∆ 24-week baseline†   −0.3 (−0.4; −0.1)  0.1 (−0.2; 0.6) 0.001
P value refers to the placebo-controlled mean effect of intervention between groups.
#Geometric mean (95% CI) or †median (interquartile range).
LAR, leptin:adiponectin ratio; SAT, subcutaneous adipose abdominal tissue; TAT, total abdominal tissue; TFA, total fat area thigh; TMA, total muscle area 
thigh; TTA, total thigh area; VAT, visceral adipose tissue.
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(rs = 0.51, P = 0.04) and Δ-leptin (rs = 0.62, P = 0.003), 
whereas Δ-adiponectin was negatively associated with 
Δ-SHBG (rs = −0.53, P = 0.02). Δ-Leptin levels showed 
a trend towards negative correlation with Δ-insulin-
stimulated Rd (rs = −0.44, P = 0.051).
No other significant correlations were observed 
between Δ-adiponectin levels, Δ-leptin levels, 
Δ-leptin:adiponectin ratio, Δ-hepatic fat content and 
changes in clinical/biochemical parameters during TRT.
Discussion
We are the first to evaluate hepatic fat content during 
testosterone therapy or placebo in men with T2D using 
the currently most accurate imaging technique, MRS. 
Furthermore, we contribute data on regional fat deposits 
and assessments of leptin and adiponectin levels as well 
as the leptin:adiponectin ratio. In the present study, 
we showed that subcutaneous fat was reduced during 
TRT, whereas ectopic visceral and hepatic fat depots 
were unaltered. In addition to the observed decrease 
in adiponectin and HDL levels, this might suggest an 
increased risk of CVD during TRT, whereas the diminished 
hyperleptinaemia and leptin:adiponectin ratio could be 
beneficial regarding the risk of CVD.
Thigh and regional abdominal fat
We found a reduction in TFA and SAT during TRT, whereas 
VAT was unaltered. Reports on the effect of TRT on regional 
abdominal adipose tissue in ageing men without T2D 
have been inconsistent possibly due to the application of 
different methods for assessment of regional abdominal 
adipose tissue (MRI, CT or ultrasound), inclusion of 
various patient cohorts and the use of a variety of 
testosterone doses and administration forms (oral, patch, 
gel or injections) (19). Our results are in accordance with 
results from studies using a sufficient testosterone dose 
in ageing men without T2D reporting a decrease in SAT 
(19, 50 51, 52) and TFA (19, 51), but no change in VAT 
(19, 50 51, 52) during TRT. In contrast, an older study by 
Marin et al. (54) in 31 middle-aged obese men with higher 
baseline testosterone levels reported unchanged SAT 
and a decrease in VAT assessed by CT despite no change 
in TFM and lean body mass (53). The lack of change 
in TFM in that study suggests that the decrease in VAT 
during TRT might be attributed to other changes during 
the experiment. In ageing men with T2D, two previous 
studies have evaluated regional abdominal fat by MRI 
during TRT and correspondingly reported a reduction 
in total body subcutaneous fat mass (30), a reduced 
amount of SAT (31), unchanged VAT (30, 31), while TFA 
was not reported (30, 31). There is evidence that lower 
body subcutaneous fat protects against CVD (11), and this 
Figure 1
Mean change (%) in subcutaneous thigh fat area (TFA), 
subcutaneous abdominal adipose tissue (SAT), visceral adipose 
tissue (VAT) and hepatic fat content. Data are presented as 
mean ± s.e.m.
Figure 2
Mean change (%) in adiponectin, leptin and 
leptin:adiponectin ratio (LAR). Data are presented as 
mean ± s.e.m.
PROOF ONLY
Eu
ro
p
ea
n
 J
o
u
rn
al
 o
f 
En
d
o
cr
in
o
lo
g
y
177:2 164Clinical Study L V Magnussen and others Ectopic fat during testosterone 
in type 2 diabetes
www.eje-online.org
could be mediated by higher adiponectin levels. Thus, 
TFA was positively associated with serum adiponectin in 
a population-based study in young (20–29 years) healthy 
men (44). We observed a reduction in TFA accompanied 
by a decrease in adiponectin levels; however, there was 
no correlation between these variables. Whether the 
reduction in adiponectin levels observed in response to 
TRT in our study represents an unhealthy effect of TRT 
or simply reflects the overall reduction in TFM remains to 
be established.
Hepatic fat content
To our knowledge, we are the first to assess the effect 
of TRT on hepatic fat content with the ‘gold-standard’ 
imaging method MRS (54) in a homogenous cohort of 
aging men with T2D. We hypothesized that hepatic fat 
content would decrease in response to TRT either as a 
consequence of reduced TFM (31, 35) or due to increased 
lipid oxidation (39, 40, 41). However, we observed no 
change in hepatic fat content measured by MRS. Stable 
VAT and hepatic fat content during TRT are consistent 
with the lack of change in insulin sensitivity evaluated 
by euglycemic–hyperinsulinemic clamp in our study as 
previously reported (35). In our study, overnight fasting 
FFA levels were not changed during TRT (35). This is in 
line with unchanged hepatic fat content during TRT 
according to the portal/visceral hypothesis stating that 
an increase in VAT is associated with rise in portal vein 
plasma FFAs (12). In support of our results, a recent study 
in men with T2D showed unchanged hepatic fat content 
during TRT assessed by MRI (30). Similarly, in men without 
T2D, two previous studies showed unchanged hepatic fat 
content during TRT (34, 36), whereas one study reported 
Table 3 Association analyses for adiponectin, leptin and leptin:adiponectin ratio (LAR): univariate correlations with clinical/
biochemical parameters at baseline.
Parameter n Adiponectin P value Leptin P value LAR P value
Age (years) 39 0.39 0.01 −0.05 0.78 −0.27 0.1
BMI (kg/m2) 39 −0.09 0.6 0.7 <0.001 0.58 <0.001
Waist circumference (cm) 39 −0.15 0.37 0.74 <0.001 0.68 <0.001
Total fat mass (kg) 38 −0.09 0.57 0.74 <0.001 0.62 <0.001
TFA/TTA (%) 25 0.11 0.6 0.14 0.52 0.02 0.92
VAT/TAT (%) 25 −0.12 0.57 0.45 0.03 0.42 0.04
SAT/TAT (%) 25 0.05 0.83 0.24 0.25 0.1 0.65
Hepatic fat/water ratio 22 −0.4 0.07 0.64 0.001 0.65 0.001
HDL cholesterol (mmol/L) 37 0.64 <0.001 −0.18 0.29 −0.55 <0.001
Triglycerides (mmol/L) 37 −0.55 <0.001 0.08 0.65 0.4 0.01
Total testosterone (nmol/L) 39 0.05 0.77 −0.47 0.002 −0.42 <0.001
Bio testosterone (nmol/L) 39 −0.06 0.71 −0.37 0.02 −0.28 0.09
Free testosterone (nmol/L) 39 −0.06 0.73 −0.38 0.02 −0.29 0.08
SHBG (nmol/L) 39 0.27 0.09 −0.4 0.01 −0.47 0.003
DHT (nmol/L) 39 0.12 0.47 −0.72 <0.001 −0.59 <0.001
HOMA-IR 38 −0.35 0.03 0.7 <0.001 0.76 <0.001
Insulin-stimulated Rd (mg/min/m2) 39 0.09 0.6 −0.56 <0.001 −0.52 <0.001
Spearman’s rank correlation.
SAT, subcutaneous adipose abdominal tissue; TAT, total abdominal tissue; TFA, total fat area thigh; TMA, total muscle area thigh; TTA, total thigh area; 
VAT, visceral adipose tissue.
Table 4 Association analyses for hepatic fat content: 
univariate correlations with clinical/biochemical parameters at 
baseline.
 
Parameter
 
N
Hepatic fat 
content
 
P value
Age (years) 22 −0.31 0.16
BMI (kg/m2) 22 0.61 0.002
Waist circumference (cm) 22 0.53 0.01
Total fat mass (kg) 21 0.49 0.02
TFA/TTA (%) 20 −0.08 0.73
VAT/TAT (%) 20 0.42 0.07
SAT/TAT (%) 20 0.34 0.15
ALAT (U/L) 22 0.63 0.002
GGT (U/L) 22 0.4 0.07
HDL-cholesterol (mmol/L) 20 −0.29 0.21
Triglycerides (mmol/L) 20 0.21 0.37
Total testosterone (nmol/L) 22 −0.1 0.64
Bio testosterone (nmol/L) 22 −0.11 0.63
Free testosterone (nmol/L) 22 −0.09 0.68
SHBG (nmol/L) 22 −0.21 0.36
DHT (nmol/L) 22 −0.22 0.33
HOMA-IR 22 0.55 0.01
Insulin-stimulated Rd (mg/min/m2) 22 −0.69 <0.001
Spearman’s rank correlation.
SAT, subcutaneous adipose abdominal tissue; TAT, total abdominal tissue; 
TFA, total fat area thigh; TMA, total muscle area thigh; TTA, total thigh 
area; VAT, visceral adipose tissue.
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reduced hepatic fat content (33). However, the reduction 
of hepatic fat content during TRT was assessed by the 
less precise CT in the RCT by Hoyos  et  al. (33). Besides 
being more obese, younger, and without T2D, the patients 
underwent a weight loss programme in addition to the 
TRT thus attenuating the conclusions that can be drawn 
from the study by Hoyos et al. (33).
Adiponectin and CVD risk
We observed a potentially unhealthy reduction in 
adiponectin levels during TRT even though the study 
cohort already at baseline had adiponectin levels 
comparable to adiponectin levels in the lowest quartile 
of men with T2D (n = 741) (55). A population-based study 
in healthy young men reported that adiponectin levels 
were inversely associated with SAT rather than VAT, 
whereas adiponectin levels were positively associated 
with TFA (44). However, in the present study, we could 
not demonstrate similar correlations at baseline, and we 
found no relationships between the change in adiponectin 
levels during TRT and changes in TFM, TFA, SAT and 
VAT. Our data suggest that TRT reduced adiponectin 
levels independent of changes in fat distribution, and 
this supports the view that TRT suppresses adiponectin 
levels through either a direct inhibition of the 
production or secretion and/or an increased breakdown 
of adiponectin (43). Previous studies in ageing men 
with T2D have reported that adiponectin levels were 
decreased (46), unchanged (30, 31) or increased (45) 
during TRT. However, in the study by Heufelder  et  al. 
(45), the modest elevation in adiponectin levels during 
TRT was quantitatively difficult to distinguish from the 
effect of diet and exercise in both the TRT and placebo 
group  (45). In RCT’s reporting unchanged adiponectin 
levels during TRT (30, 31), included patients were more 
obese compared to our study. Thus, a larger decrease in 
TFM, as normally seen (15), could have contributed to 
an increase in adiponectin, which then would hide the 
decrease in adiponectin levels likely caused by a direct 
effect of TRT. Our baseline data support a link between 
high adiponectin levels and healthier cardiometabolic 
profile as adiponectin levels were positively associated 
with HDL cholesterol and negatively associated with 
levels of TG and HOMA-IR, respectively; TRT aggravated 
this profile. Thus, the decrease in both levels of 
adiponectin and HDL cholesterol during TRT in our 
study might suggest a worsened cardiometabolic profile. 
However, the clinical impact may be minor considering 
the low adiponectin levels at baseline.
Leptin, leptin:adiponectin ratio and CVD risk
We confirmed that obesity assessed by TFM, BMI and 
WC was associated with higher levels of leptin and 
leptin:adiponectin ratio at baseline (56), and our data 
also suggested that levels of leptin and leptin:adiponectin 
ratio were closer associated with hepatic fat content and 
VAT than the subcutaneous fat compartments (SAT, TFA). 
Previous studies reported that leptin levels were more 
strongly associated with SAT than VAT (20, 22). However, 
in the study by Neeland  et  al. (20), leptin levels were 
actually associated with VAT in obese men but not in 
women (20). Although baseline leptin levels correlated 
inversely with measures of circulating testosterone in 
our study, the 20–30% reduction in levels of leptin and 
leptin:adiponectin ratio during TRT did not correlate with 
changes in any of the regional fat compartments (TFA, 
SAT, VAT, hepatic fat content). Together these findings 
might imply a potential direct suppressive effect of TRT on 
leptin levels, which may be independent of the reduction 
in the regional fat deposits. No other study has reported 
levels of leptin and leptin:adiponectin ratio in relation 
to regional fat compartments assessed by MRI, CT and/
or MRS in ageing men with T2D. In accordance with our 
findings, other RCTs have reported decreased leptin levels 
during TRT in men with T2D (30, 46, 57).
Overall, the findings that levels of leptin and 
leptin:adiponectin ratio were related to markers of 
increased CVD risk such as increased ectopic fat, a 
poorer lipid profile and lower insulin sensitivity and 
that levels of leptin and leptin:adiponectin ratio were 
reduced in response to TRT, suggest that the amelioration 
in hyperleptinaemia during TRT even when adjusted 
for adiponectin may be beneficial regarding the CVD 
risk (27, 29).
Strengths and limitations
We have used the ‘gold-standard’ imaging method MRS 
in evaluating hepatic fat content in a homogenous 
patient cohort in which all patients were diagnosed with 
T2D. Gold-standard method was applied for testosterone 
measurement. We performed per-protocol analyses 
with a low drop-out rate, and no drop-outs were due to 
lack or adverse effects of the gel. The average duration 
PROOF ONLY
Eu
ro
p
ea
n
 J
o
u
rn
al
 o
f 
En
d
o
cr
in
o
lo
g
y
177:2 166Clinical Study L V Magnussen and others Ectopic fat during testosterone 
in type 2 diabetes
www.eje-online.org
of T2D was relatively short (3–4  years). The included 
patients with T2D were relatively well controlled on 
stable antidiabetic treatment with metformin alone and 
had fasting insulin levels demonstrating the absence 
of marked beta-cell failure. This design was chosen to 
exclude T2D patients with increasing pancreatic beta-
cell failure, and hence, poorer and more variable HbA1c 
levels, which would increase the need for change in 
antidiabetic medication. To our knowledge, there is no 
reason to believe that TRT improves beta-cell function, 
and therefore, no reason to include T2D patients with 
marked beta-cell failure, poorer glycemic control and 
need for further antidiabetic drugs. Furthermore, no 
changes of the antidiabetic treatment (metformin) or 
the cholesterol-lowering drugs were allowed throughout 
the study as any change would have compromised the 
achievement of valid results. Thus, it is not possible to 
generalize the observed effects of TRT in our study to all 
men with T2D.
Unfortunately, we were not able to establish a 
quantitative measure for hepatic fat content, only a 
change. Thus, we cannot determine whether the content 
of hepatic fat was actually different between groups at 
baseline. However, our results on hepatic fat content are 
not influenced by this limitation. Regrettably, the patients 
had difficulties in completing the MRI and MRS scans due 
to obesity, claustrophobia and failure in the acquisition 
of the MRI/MRS scans, which resulted in a considerable 
drop-out rate. We acknowledge the limitations of our 
results regarding hepatic, visceral and subcutaneous fat 
deposits by these drop-outs of patients from MRI/MRS 
scans, and we cannot exclude a type II error. However, 
the data reported on hepatic fat are obtained using the 
currently most accurate method.
In conclusion, the effects of TRT on cardiovascular 
risk markers were ambiguous. On one hand, we observed 
potentially harmful changes in cardiovascular risk 
parameters, markedly reduced subcutaneous fat (TFA and 
SAT), unchanged ectopic fat (VAT and hepatic) during 
TRT and a reduction in adiponectin levels. On the other 
hand, the decrease in leptin levels and leptin:adiponectin 
ratio could reflect an amelioration of the cardiovascular 
risk profile linked to hyperleptinaemia in ageing men 
with T2D.
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